CAMKK2 is generally upregulated in several cancers, including prostate cancer, and high expression of CAMKK2 was correlated with poor overall survival in hepatocellular carcinoma and glioma 48-50. This evidence concerns the gene CAMKK2 and central nervous system cancer.